VanGuard Plus 5 vaccine

Indications

• Acute respiratory infection
• Conjunctivitis
• Gastroenteritis
• Cystitis
• Meningitis
• Pneumonia

Dosage

Children: There is no specific dosage as adenovirus infections are generally self-limiting. Symptomatic treatment is advised.

Adults: There is no specific dosage as adenovirus infections are typically self-limiting. Supportive care is recommended.

Mechanism of action

Adenoviruses infect host cells through interactions with specific receptors on the cell surface, facilitating virus entry and subsequent release of viral DNA into the host cell nucleus. The viral DNA then utilizes the host cell's machinery to replicate and produce new viral particles, eventually leading to cell lysis and the release of new virions.

Pharmacodynamics

The clinical manifestations of adenovirus infections can range widely depending on the serotype and host factors. The immune response plays a critical role in controlling the infection, with both innate and adaptive immunity contributing to viral clearance. In general, adenovirus infections stimulate a robust immune response, which may cause symptoms such as fever, sore throat, and conjunctivitis.

Pharmacokinetics

Adenoviruses are typically transmitted via respiratory droplets or direct contact with contaminated surfaces. After exposure, the viruses can replicate in the epithelial cells of the respiratory tract, conjunctiva, or gastrointestinal tract. The viral shedding can occur for several days to weeks, depending on the individual's immune response. Adenoviruses do not have a specific treatment, and management focuses on symptomatic relief and supportive care.

Adverse effects

• Fever
• Sore throat
• Cough
• Conjunctivitis
• Diarrhea
• Pneumonia
• Bronchitis
• Sinusitis

Precautions

• In immunocompromised patients, adenovirus can cause severe disease.
• Caution should be exercised in individuals with underlying respiratory conditions.

Pregnancy

Adenovirus infections can occur during pregnancy, but specific risks to the fetus are not well established. Consultation with healthcare providers is advised.

Breast-feeding

Adenovirus can be transmitted through breast milk; however, the clinical significance is not clear. Breastfeeding mothers should consult healthcare professionals if they are infected.

Storage

Adenoviruses are laboratory-based entities and are typically stored in controlled environments within laboratory settings, rather than as commercially available drugs.

Indications

• Chronic pain management
• Neuropathic pain
• Multiple sclerosis spasticity
• Seizure disorders (e.g., epilepsy)
• Nausea and vomiting associated with chemotherapy
• Appetite stimulation in conditions like HIV/AIDS

Dosage

Adults: Refer to the specific product guidelines and clinical protocols, as dosing can vary significantly based on individual response, specific condition, and formulation used

Mechanism of action

Cannabinoids exert their effects primarily through the activation of cannabinoid receptors, mainly CB1 and CB2, which are part of the endocannabinoid system. CB1 receptors are predominantly found in the central nervous system and are involved in the modulation of neurotransmitter release, while CB2 receptors are primarily located in the peripheral nervous system and immune cells, influencing inflammation and immune response. This interaction leads to various physiological effects such as reduced pain perception and modulation of immune function.

Pharmacodynamics

The pharmacodynamics of cannabinoids involve their interaction with the endocannabinoid receptors, leading to a range of effects. CB1 receptor activation can result in decreased neurotransmitter release, which contributes to analgesic effects, appetite stimulation, and mood modulation. CB2 receptor activation is associated with anti-inflammatory effects and immune modulation. The overall effects depend on the specific cannabinoid, its dose, and the individual's unique receptor profile.

Pharmacokinetics

Cannabinoids are typically administered via inhalation, oral ingestion, or topical application. Following administration, they undergo rapid absorption, with peak plasma concentrations achieved within minutes to hours depending on the route. The distribution of cannabinoids occurs throughout the body, with a high affinity for fat tissues due to their lipophilic nature. Metabolism primarily occurs in the liver via cytochrome P450 enzymes, resulting in various metabolites, some of which may have pharmacological activity. Elimination half-life varies widely, influenced by the route of administration and individual metabolic rates, typically ranging from hours to several days.

Contra-indications

• Hypersensitivity to cannine or any of its components
• Severe hepatic impairment
• Severe renal impairment

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Headache
• Fatigue
• Dry mouth
• Constipation
• Increased liver enzymes

Interactions

• Caution is advised when used with other medications that affect liver enzymes
• May enhance the effects of central nervous system depressants
• Potential for additive effects with other drugs that cause sedation

Precautions

• Use with caution in patients with a history of liver disease
• Monitor liver function tests periodically during treatment
• Consider potential for drug interactions
• Assess for history of substance abuse

Pregnancy

Limited data on use in pregnancy. Should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not known whether cannine is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place, away from moisture and light. Keep out of reach of children.

Formulations

• Tablets
• Oral solution
• Injectable form

Indications

• Prevention of canine distemper through vaccination
• Supportive treatment for infected dogs

Dosage

Children: No specific dosage available, refer to guidelines for vaccination schedules.

Adults: No specific dosage available, refer to guidelines for vaccination schedules.

Mechanism of action

Canine distemper virus primarily infects and replicates in lymphoid tissue, leading to immune suppression, and subsequently affects epithelial tissues in the respiratory, gastrointestinal, and nervous systems. The virus enters host cells via the signaling lymphocytic activation molecule (SLAM) receptor, which is expressed on immune cells, facilitating its spread throughout the body.

Pharmacodynamics

The immune response to CDV involves both humoral and cellular immunity. Vaccination induces an immune response that generates neutralizing antibodies, which prevent viral entry into host cells. Infected animals may develop severe immunosuppression, making them susceptible to secondary infections. The clinical manifestations depend on the severity of the infection and the host's immune response.

Pharmacokinetics

The pharmacokinetics of canine distemper virus are not typically described in terms of absorption, distribution, metabolism, and excretion like conventional drugs. Instead, the focus is on viral replication and the host immune response. The incubation period for distemper can vary but generally ranges from 1 to 2 weeks. The duration of the immune response post-vaccination can last for several years, depending on the type of vaccine used.

Pregnancy

No specific data available on the effects of distemper treatment in pregnant individuals, consult relevant guidelines.

Breast-feeding

No specific data available on the effects of distemper treatment during breastfeeding, consult relevant guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Leptospirosis
• Severe leptospirosis with renal failure
• Leptospirosis with jaundice
• Leptospirosis with pulmonary hemorrhage

Dosage

Children: Refer to specific pediatric dosing guidelines for the treatment of leptospirosis based on the chosen antibiotic

Adults: Refer to specific antibiotic guidelines for treatment of leptospirosis, typically involving doxycycline or penicillin, depending on the severity and clinical presentation.

Mechanism of action

Leptospira bacteria penetrate the mucous membranes or broken skin, entering the bloodstream and disseminating throughout the body. They evade the immune system and can replicate within host tissues, leading to an inflammatory response. The bacteria primarily target the liver and kidneys, causing cellular damage and dysfunction. Antibiotics such as doxycycline or penicillin are effective in inhibiting bacterial growth and promoting clearance from the body.

Pharmacodynamics

Antibiotics used to treat leptospirosis work by inhibiting bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, depending on the class of antibiotic. This results in bacterial cell death or inhibition of growth. The immune response is also activated, assisting in the clearance of the infection. The severity of symptoms and the extent of organ involvement may influence the pharmacodynamic response to treatment.

Pharmacokinetics

The pharmacokinetics of antibiotics used for leptospirosis varies by the specific medication. For instance, doxycycline is well-absorbed after oral administration, with a bioavailability of approximately 90%. It is distributed widely in body tissues and fluids, and it is primarily excreted in urine. Penicillin, on the other hand, is less well-absorbed orally but is effective when given parenterally, with rapid distribution to body tissues. Both drugs undergo renal elimination, making dose adjustments necessary in patients with renal impairment.

Adverse effects

• Fever
• Headache
• Muscle aches
• Red eyes
• Jaundice
• Abdominal pain
• Diarrhea
• Rash
• Cough
• Meningitis
• Kidney damage

Precautions

• Use caution in individuals with liver disease
• Monitor renal function in patients with renal impairment
• Consider the potential for severe illness in pregnant women

Pregnancy

Limited data available; consult healthcare professionals for risks and benefits.

Breast-feeding

Limited data available; consult healthcare professionals for risks and benefits.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Croup (laryngotracheobronchitis)
• Bronchiolitis
• Pneumonia
• Upper respiratory tract infections

Mechanism of action

Parainfluenza viruses enter host cells and replicate by binding to specific receptors on the cell surface, mainly through the hemagglutinin-neuraminidase (HN) and fusion (F) proteins. Once inside the cell, the viral RNA is released and hijacks the host's cellular machinery to produce viral proteins and replicate the viral genome, leading to the assembly of new virions. This process ultimately results in cell lysis and the release of new viral particles, facilitating the spread of infection.

Pharmacodynamics

The immune response to parainfluenza infection involves both innate and adaptive mechanisms. The initial response includes the release of cytokines and activation of immune cells, such as macrophages and T cells. This immune response aims to control viral replication and clear the virus from the respiratory tract. Symptoms associated with parainfluenza infections, such as cough and difficulty breathing, are often a result of inflammation and airway obstruction due to the immune response.

Pharmacokinetics

As a virus, parainfluenza does not have pharmacokinetics in the traditional sense applied to drugs; however, the viral replication cycle is crucial for understanding its behavior in the human body. Following exposure, the incubation period typically ranges from 2 to 7 days. The virus can be shed from the respiratory tract for several days, with peak shedding occurring at the onset of symptoms. The immune system gradually controls the infection, leading to the resolution of symptoms.

Adverse effects

• Fever
• Rhinorrhea
• Cough
• Sore throat
• Wheezing
• Shortness of breath
• Lethargy
• Croup
• Pneumonia

Precautions

• Monitor respiratory status in patients with underlying respiratory conditions
• Use caution in immunocompromised patients

Pregnancy

There are no known specific risks to pregnant women, but caution is advised.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.